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Abstract
Background: To assess reduction in heavy menstrual bleeding and dysmenorrhea following MRI guided
Focused Ultrasound Surgery (MRgFUS) of focal and diffuse adenomyosis up to 12 months post-treatment
a retrospective cohort study was done at a tertiary care academic medical center for obstetrics, gynecology
and infertility.
Methods: MRgFUS for adenomyosis uterus was done for thirty-seven patients presenting with symptoms of
heavy menstrual bleeding and dysmenorrhea with MRI-suspected adenomyosis. The main outcome measure,
was reduction in heavy menstrual bleeding, dysmenorrhea and Symptom Severity Scoring (SSS) over a 3, 6
and 12 month period. Secondary outcome was evidence of fertility preservation post procedure. D’Agostino &
Pearson omnibus normality test, one-way Ananova, Pearson’s correlation coefficient analysis was performed on
the data. Statistical significances, p-value and r-value were determined.
Results: Out of 37 patients who were treated by MRgFUS, 26 had sufficient follow-up to be included in
the analysis. SSS calculated at 3, 6 and 12 months was significantly over the baseline. Both heavy menstrual
bleeding and dysmenorrhea, which were assessed separately, were found to significantly improve over time
with a positive correlation between the two. No other intervention was required.
Conclusion: MRgFUS provides immediate and sustained relief for patients with focal and diffuse adenomyosis.
Keywords: MRI guided Focussed Ultrasound Surgery (MRgFUS), Adenomyosis, Uterus sparing surgery, Fertility
preservation
Background
Adenomyosis is defined as a benign invasion of endo-
metrium into the myometrium, producing a diffusely en-
larged uterus which microscopically exhibits ectopic,
non-neoplastic, endometrial glands and stroma sur-
rounded by the hypertrophic and hyperplastic myome-
trium [1]. While adenomyosis is strictly a pathological
diagnosis, there is consensus now that MRI indicates the
presence of adenomyosis when the junctional zone (JZ)
thickness is > 12 mm [2].
Adenomyosis is usually diagnosed between 30 and
45 years of age [3], with an 8–27 % prevalence [4]. The
increased incidence of younger women presenting with
infertility and subsequently being diagnosed with adeno-
myosis may be the result of enhanced diagnostic capabil-
ities. MRI is currently regarded as the best imaging tool
for differential diagnosis between uterine fibroids and
adenomyosis [5, 6]. However, MRI is not routinely used
for the evaluation of these pathologies. A correct differ-
ential diagnosis is critical, because the optimal treatment
modalities for these two entities may differ. Specifically, in
women with symptomatic leiomyomas, uterine-conserving
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surgical therapy is well-established, whereas hysterectomy
remains the treatment of choice for debilitating adenomyo-
sis [7]. In contrast to uterine leiomyoma, adenomyosis is
not demarcated from the adjacent myometrium by a cap-
sule. Difficulty in defining the location and the extent of
adenomyosis often makes it difficult to determine the feasi-
bility and extent of complete excision when attempting to
preserve the uterus [8]. Women with diffuse disease are
often not considered as candidates for conservative surgery.
Removal of adjacent healthy myometrium may increase the
risk of bleeding and extensive damage to the uterine wall
and could negatively affect the tensile strength of the uterus
during pregnancy and labour and, thus, the ability of the
uterus to carry future pregnancies safely to term [8, 9].
Symptoms of adenomyosis include heavy menstrual
bleeding, dysmenorrhea and pelvic pressure and fre-
quent urination from uterine enlargement. The sever-
ity of symptoms correlates roughly with the extent of
disease [2, 10, 11]. Newer reports using MRI criteria
for diagnosis suggest that the disease may cause dys-
menorrhea and chronic pelvic pain in adolescents and
women of younger reproductive age than previously
appreciated [12, 13].
Magnetic resonance-guided focused ultrasound sur-
gery (MRgFUS) has been used successfully over the past
years for the conservative treatment of uterine leiomyo-
mas, without damage to surrounding healthy myome-
trium and without major morbidity [9, 14]. It is a non-
invasive technique for the ablation of soft tissue that of-
fers a new approach to conservative non-invasive uterine
surgery [9] Sequential ultrasound beams are precisely
focused on a series of small foci within the larger target
volume to locally heat tissue under real-time MR
guidance and control, causing thermal coagulation and
subsequent tissue necrosis in a precisely defined area.
The first published case report of a pregnancy and live
birth after focused ultrasound surgery for symptomatic
focal adenomyosis was by Rabinovici et al [15]. Owing to
the accuracy and precision of this technique, it has been
hypothesized that MRgFUS could also treat adenomyosis
accurately and successfully without deleterious effects
on the surrounding myometrium and on subsequent
fertility [15].
Previously published literature on the utilisation of
MRgFUS for adenomyosis with short-term (3 and
6 months) and long-term (upto 2 years) follow-up has
indicated that the treatment was safe and that there was
significant reduction in symptoms overall [11, 16, 17].
However, the Symptom Severity Score (SSS) (UF-QOL)
scoring which is used to assess the symptoms of patients
before and after MRgFUS treatment for fibroids, is not
specific for adenomyosis and does not assess dysmenor-
rhea, one of the most debilitating symptoms associated
with adenomyosis.
The objective of this study was to evaluate the degree
of reduction of dysmenorrhea and heavy menstrual
bleeding after treatment with MRgFUS in patients with
focal and diffuse adenomyosis and to determine whether
MRgFUS, as a primary treatment modality, can provide
both immediate and sustained symptom relief over a 12-
month period.
Methods
Patient characteristics and inclusion criteria
Between December 2012 and April 2014, 125 patients
with symptoms of pelvic pain, heavy menstrual bleeding
and/or dysmenorrhea were screened with MRI and were
diagnosed with adenomyosis uterus. Seventy-three of the
patients screened were candidates for the MRgFUS pro-
cedure. Thirty-seven of the screened candidates without
fibroids, with symptoms of heavy menstrual bleeding
and dysmenorrhoea attributed to MRI-suspected adeno-
myosis and who wished to preserve their uterus were eli-
gible for this study.
The MRI diagnosis of adenomyosis was defined as
junctional zone thickness of >12 mm. A diagnosis of
focal adenomyosis was made when there was hyper-
trophic, distorted and localized low-signal-intensity re-
gion within the myometrium and a diagnosis of diffuse
adenomyosis was made when diffuse thickening of the
endometrial-myometrial junctional zone along with
homogeneous low signal intensity was found scattered
throughout the uterine musculature, on T2-weighted
MRI sequences. Those that did not fall into this criterion
or had abdominal wall thickness measuring over 3.5 cm
were not candidates for MRgFUS treatment. Patients
were excluded from the analysis if they had coexisting
endometriotic cysts diagnosed on MRI, were treated
with GnRH agonist or an intrauterine device after
MRgFUS treatment.
Thirty-seven patients (31.2 %) who fell in the study in-
clusion criteria opted for and were treated by MRgFUS.
Only 26 patients came back for follow-up at 3, 6 and
12 months and were included in the analysis. Eleven pa-
tients (28.2 %) did not return for the 12-month follow-
up. Of the 26 patients (66.7 %), two patients required a
second sitting due to diffuse adenomyosis, as regions
were treated separately. The scoring for these patients
was done from the second sitting which was done at
1 month interval from the first sitting. Of the 26 patients
included in the analysis, two patients have been followed
for 24 months.
All patients were counselled on the nature of the pro-
cedure and all provided informed consent for this form
of treatment. The institutional review board of Womens
Center, Coimbatore, India approved this retrospective
cohort study.
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SSS focussing on heavy menstrual bleeding and dys-
menorrhea was assessed through a questionnaire from
all patients included in the study, collected on the day of
treatment and up to 12 months (26 patients) and
24 months (2/26 patients) following treatment.
MRgFUS procedure
Patients were put on a liquid diet a day prior to the pro-
cedure. On the day of the procedure the bladder was
catheterized and the patients were given enema for
bowel preparation. Rectal filling with ultrasound gel was
done for all patients prior to the starting the procedure
in order to push the uterus anteriorly and prevent move-
ment during sonications. Mild conscious sedation with
fentanyl IV was administered prior to the start of the
treatment with subsequent sedation administered during
treatment to retain patient comfort and reduce move-
ment during the procedure. Patients were treated in the
prone position. The region of treatment (ROT) was
planned as multiple sonication spots measuring 3 to
5 mm. The therapeutic ultrasound beam was delivered
to a target area of adenomyosis raising the local
temperature to 70–90° Celsius in a matter of seconds
producing thermal coagulation of the sonicated spot.
The treated area was mapped on the software and the
operator repeatedly sonicated spots until the planned
area of adenomyosis was ablated. Safety was assured
with fiducials drawn around the ROT indicating patient
movement, real time monitoring performed with magni-
tude images and temperature feedback. Post-treatment
contrast imaging with IV gadolinum was performed to
clearly delineate the treated area (s). Only one region
was treated per session. Therefore, patients with focal
adenomyosis were treated in a single sitting and patients
with diffuse adenomyosis were treated in 2 sittings. The
average time duration per sitting was 4 h.
Symptom scoring
Due to the absence of an adenomyosis-specific question-
naire, a questionnaire designed to assess fibroid symp-
toms was used. A score from 8 questions (UF-QOL) on
the SSS was transformed to a 0–100 score [18]. A separ-
ate scoring on a scale of 1 to 5 was done for dysmenor-
rhea, 1 being lowest and 5 the highest, as the (UF-QOL)
does not include it (see Additional file 1).
Statistical analysis
Data was analysed utilising GraphPad Prism version
6.0 f. All data were subject to and passed the D’Agostino
& Pearson omnibus normality test. One-way Anova ana-
lysis (SSS, dysmenorrhea and heavy menstrual bleeding)
was performed to determine statistical significances and
a p-value of <0.05 was considered as significant. Pear-
son’s correlation coefficient analysis was performed to
determine r-value for correlation between heavy men-
strual bleeding versus dysmenorrhea over time and a
95 % confidence band of the best-fit line was utilised.
Results
Patient demographics
The median age of the patients was 33.5 (23–49) with a
median BMI of 26 (19–31.5; Table 1). Of the 26 patients
with follow-up at 12 months, 24 were treated for focal
adenomyosis (involving either the anterior wall, poster-
ior wall, or fundus) and 2 were treated for diffuse global
adenomyosis (entire uterus enlarged and globular).
Symptom outcomes
The 26 patients were included for data analysis and the
SSS score for these patients at baseline, 3, 6 and
12 months was calculated based on the UF-QOL score.
The mean SSS for each of these time points indicated
was significantly reduced to 44.95 ± 2.72, 37.64 ± 2.85
and 34.50 ± 2.89 (p < 0.0001) at 3, 6 and 12 months
respectively compared to mean SSS of the baseline
(54.83 ± 2.63) (Fig. 1). This significant reduction indi-
cates a likely improvement in the quality of life for these
patients. Of the 26 patients, two patients had follow-up
data at 18 and 24 months and in both of these patients
there was a slight increase in SSS from the 12-month
time-point.
Heavy menstrual bleeding and dysmenorrhea scores
are one of the eight components that formed part of the
SSS (UF-QOL). Mean baseline heavy menstrual bleeding
score (4.42 ± 0.12) compared to the 3, 6 and 12-month
time-points (3.42 ± 0.16, 3.03 ± 0.14 and 3.23 ± 0.18) was
found to significantly improve over time in MRgFUS
patients (p < 0.0001, Fig. 2a). Likewise, mean baseline
(4.46 ± 0.11) dysmenorrhea score compared to 3, 6 and
12- month score (3.69 ± 0.16,3.26 ± 0.17 and 3.26 ± 0.18)
was found to be significantly reduced (p < 0.0001, Fig. 2b).
Given that both dysmenorrhea and heavy menstrual
bleeding were significantly reduced over time in our
MRgFUS patients (Fig. 2a, b), the scores at matched
time-points were interrogated for correlation. Heavy
menstrual bleeding positively correlated with dysmenor-
rhea in MRgFUS patients. Analysis revealed that was a
strong positive correlation (baseline, r = 0.74; 3 month,
r = 0.75; 6 month, r = 0.68; 12 month, r = 0.72; p <
0.0001) at all time points between heavy menstrual
Table 1 Patient demographics
Total no: of patients 26
Median age (age range) 33.5 (23–49)
Median BMI (BMI range) 26 (19–31.5)
Focal Adenomyosis 24
Diffuse Adenomyosis 2
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bleeding and dysmenorrhea in these patients (Fig. 3a-
d).
Uterine imaging
A review MRI was suggested for patients at 6 and
12 months to assess the reduction in adenomyotic vol-
ume. Out of the 26 patients, only 3 patients consented
to have an MRI review at both 6 and 12 months so uter-
ine volume assessment over time could not be calculated
for the entire study group. Of the three patients, all
three had reduction of adenomyotic volume at 6 months
(2, 54, 37 %), which reduced further in one patient and a
slight increase was seen in two (9, 44, 32 %) with no
changes in SSS.
Fertility outcome
Of the 26 patients, 13 patients were infertile and
planned to start treatment for the same after the proced-
ure. The median age of those seeking fertility treatment
was 34. Of the 26, one patient who was not seeking
treatment for fertility conceived spontaneously 4 months
post MRgFUS. Of those seeking fertility treatment, only
five patients underwent assisted reproductive technology
(ART) due to cost constraints, of which two patients
conceived at 12 and 18 months post MRgFUS respect-
ively. Both patients delivered at term, one vaginally and
the other delivered through an emergency caesarean
section.
Discussion
Advances in treatment for adenomyosis have been lim-
ited by the difficulties in determining a clinical diagnosis,
appropriately defining the extent of the lesion and the
lack of a specific intervention. Different surgical and
medical modalities of treatment have been addressed in
the literature but many of these have not been tested
specifically for adenomyosis uteri. In the absence of
treatments directed at the disease itself, management is
often directed at the symptoms [19]. MRgFUS has been
used effectively for the non-invasive ablation of patho-
logic tissue [9, 14]. It has been hypothesized that
MRgFUS could also treat adenomyosis accurately and
successfully without deleterious effects on the surround-
ing myometrium and on subsequent fertility [15].
In our study, we utilised MRgFUS for adenomysis pa-
tients and found that there was significant reduction of
SSS at 3, 6 and 12 months post-treatment (44.95 ± 2.72,
Fig. 1 Reduction of symptom severity score (SSS) in patients
undergoing MRgFUS. Scatter dot plot of the mean SSS in 26
adenomyosis patients undergoing MRgFUS treatment at baseline, 3,
6 and 12 months. One-way ANOVA analysis indicated a significant
reduction in the mean score at 3, 6 and 12 months compared to
baseline SSS (**** - p < 0.0001)
Fig. 2 a Dysmenorrhea significantly reduces over time. Bar graph of
the mean dysmenorrhea score at baseline, 3, 6 and 12 months in
26 adenomyosis patients undergoing MRgFUS treatment. One-way
ANOVA analysis indicated a significant reduction in the mean score
at 3, 6 and 12 months compared to baseline dysmenorrhea score
(**** - p < 0.0001). b Heavy menstrual bleeding significantly reduces
over time. Bar graph of the mean heavy menstrual bleeding score in
26 adenomyosis patients undergoing MRgFUS treatment at baseline,
3, 6 and 12 months. One-way ANOVA analysis indicated a significant
reduction in the mean score at 3, 6 and 12 months compared to
baseline menorrhagia score (**** - p < 0.0001)
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37.64 ± 2.85, 34.50 ± 2.89 respectively). Of the 26 pa-
tients, two patients had follow-up data at 18 and
24 months and, in both of these patients there was a
slight increase in SSS at 18 and 24 months (Fig. 1b). This
finding is in line with the nature of the disease and the
possibility of recurrence. In addition, none of the pa-
tients included in our analysis received hormonal injec-
tions or any other interventions post MRgFUS.
Women with diffuse adenomyosis are often not con-
sidered as candidates for conservative surgery [20]. In
our study, of the 37 patients who were treated by
MRgFUS, a total of 6 (16.21 %) patients had diffuse ade-
nomyosis. But of this number only 2 were included in
the analysis as the remaining patients were lost to follow
up. Of the two patients for whom we had follow up at
3,6 and 12 months, one patient had significant
improvement of SSS from a baseline score of 66.25 %
(50.0, 50.0 and 46.87 % respectively). The other patient
had reduction of SSS at 3 months (25.0 %) and 6 months
(25.0 %) from a baseline score of 40.62 %. But her score
increased to 65.60 % by 1 year post treatment. Further
studies with larger number of patients are required to
support the use of MRgFUS in treating diffuse adeno-
myosis effectively.
Amongst women with symptomatic adenomyosis,
heavy menstrual bleeding and dysmenorrhea are the two
major grievances [21]. Several publications describe
short term and long term follow-up of SSS in patients
who have been treated using MRgFUS for adenomyosis
indicating that the treatment was safe and that there was
significant reduction in symptoms. In all these studies,
the assessments of SSS have been based on the UF-QOL
Fig. 3 a-d Correlation of dysmenorrhea vs heavy menstrual bleeding at baseline, 3, 6 and 12 months. Correlation plot of dysmenorrhea vs
menorrhagia at a baseline, b 3 months, c 6 months and d 12 months indicates a significant correlation across all time points with r and p values
as indicated below each graph
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questionnaire. None of these papers specifically look at
dysmenorrhea, the most disabling symptom [11, 16, 17].
There is also a lack of consensus in the literature regard-
ing the relationship between adenomyosis and heavy
menstrual bleeding [22].
In our study, we assessed dysmenorrhea separately as
it is not a part of the UF-QOL questionnaire. We found
a significant reduction in dysmenorrhea at 3, 6 and
12 months respectively (Fig. 2a). In the two patients for
whom we had an 18 and 24 month follow-up, we found
that there was sustained relief of dysmenorrhea up to
24 months. In addition, when heavy menstrual bleeding
was assessed individually, there was a significant reduc-
tion in the scoring at 3, 6 and 12 months respectively
(Fig. 2b). Heavy menstrual bleeding and dysmenorrhea
are both positively associated with the depth of
penetration of individual adenomyotic glands into the
myometrium [1, 23]. In our study we found a positive
correlation between the reduction of heavy menstrual
bleeding and dysmenorrhea at 3, 6 and 12 months.
Limitations of the study
The first limitation of the study was the absence of a
tool for evaluating patients with the spectrum of symp-
toms related specifically to adenomyosis, we had to
evaluate symptoms of patients before and after treat-
ment of adenomyosis using MRgFUS with the help of a
questionnaire which is traditionally used to evaluate
symptoms associated with fibroids. We had to design a
score specifically for assessing dysmenorrhoea, as it was
not a part of the UF-QOL questionnaire. The next limi-
tation was the difficulties faced to get follow-up at 3, 6
and 12 months for all treated patients thereby limiting
our study population. Patients who could not come in to
the hospital for assessment were followed up through
phone calls. Some patients were lost to follow up after a
single post treatment assessment. In order to evaluate
the overall size reduction in the extent of adenomyosis
and the overall uterine volume post MRgFUS treatment,
an MRI scan was suggested at 6 and 12 months follow
up visit. But as a majority of Indian insurance companies
did not cover the procedure during the study period;
MRI assessment at both 6 and 12 months follow-up was
performed only for 3/26 patients. This was a major draw
back faced during the study as the symptomatic changes
could not be correlated with the structural changes in
the uterus post treatment in significant number of
patients. Of the three patients with MRI follow-up,
adenomyotic volume reduced at 6 months, which re-
duced further in one patient and a slight increase was
seen in the other two. Despite the increase in volume,
there was no change in the SSS. This is significant as it
also shows that increase in volume may not necessarily
cause an increase in the symptoms of dysmenorrhea and
heavy menstrual bleeding.
The role of adenomyosis in infertility is still debated:
the association between adenomyosis and sterility is
poorly understood (occurring in between 1 and 14 % of
the cases in the literature) but the frequency of infertility
has not been assessed in large studies [24]. There is no
consensus on appropriate management of symptomatic
adenomyosis in women seeking fertility [25]. The con-
cept of conservative uterus – sparing surgery is increas-
ing but it has not yet become the standard [26]. It
involves techniques that modify the anatomy of the
uterus and this may contribute to a declined post preg-
nancy rate [27]. Of those seeking fertility treatment post
MRgFUS in our study population (13/26), treatment for
infertility was started 3 months post MRgFUS. Two pa-
tients conceived with assisted reproductive technology
(ART) with ongoing pregnancies at 12 and 18 months
post MRgFUS respectively. Their infertility workup did
not demonstrate any abnormal findings other than an
enlarged uterus. Of the 26, one patient who was not
seeking treatment for fertility conceived spontaneously
5 months post MRgFUS. Her pregnancy was uneventful
and she gave birth to a healthy male baby at term fol-
lowing a normal vaginal delivery.
Conclusion
In summary, this study is significant as it provides evi-
dence that for symptomatic adenomyosis, focal or dif-
fuse, MRgFUS can be used as a safe and effective
treatment modality for immediate as well as sustained
improvement in quality of life, especially in respect to
the most significant symptoms of heavy menstrual
bleeding and dysmenorrhoea, without any add back
treatment such as GNRH analogues or Levonorgestrel
IUD (LNG). Since MRgFUS is a non-invasive treatment
modality, it should be feasible to perform MRgFUS for
patients even with relapsed adenomyosis. In our center,
we have on going studies on the time interval to relapse
of adenomyosis following MRgFUS and effectiveness of
combined approach of MRgFUS followed by LNG inser-
tion for sustained symptomatic relief in patients as an al-
ternate to hysterectomy. Further larger studies are
needed to refine the optimal patient population for this
procedure and to assess how the MRgFUS compares to
other uterus sparing treatment modalities.
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